Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Whitepaper

Best Practices in Formulation and Lyophilization Development: Proteins, monoclonal Antibodies (mAb), and Antibody Drug Conjugates (ADC)

The ultimate goal of formulation development is a stable product. In the case of a protein product, that can be defined as delivering the correct dose, in the native secondary and tertiary structure, without unintended chemical modifications and free of extrinsic and intrinsic particles.

In many cases, a lyophilized formulation can provide the highest probability of technical success. A well-designed product development plan can develop a Phase I product quickly, while laying the foundation for commercial product success.

Download this free whitepaper to find out more about Baxter’s best practices in formulation and lyophilization development, including development approach, establishment and optimization of a conservative lyophilization cycle, and stability studies.

Best Practices in Formulation and Lyophilization Development: Proteins, monoclonal Antibodies (mAb), and Antibody Drug Conjugates (ADC)

For Free, instant access, click below.

Download Whitepaper

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.




Thank You

Your white paper is now downloading... Click here if the download does not begin.

Go Top